Connect Biopharma Holdings (CNTB) Income from Continuing Operations (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Income from Continuing Operations of 19398000.0 for Q1 2026, down 28.39% sequentially from 15109000.0 in Q4 2025, and down 88.84% YoY from 173871078.53 in Q1 2025.
Connect Biopharma Holdings (CNTB) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Income from Continuing Operations for 3 years, with the latest figure at 19398000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 88.84% year-over-year to 19398000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 64606000.0 (down 275.46% YoY) and the FY2025 annual result came in at 55480000.0, down 255.0% from the prior year.
- Income from Continuing Operations fell to 19398000.0 in Q1 2026 per CNTB's latest filing, from 15109000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 14847000.0 in Q2 2024 and troughed at 19398000.0 in Q1 2026.
- A 3-year average of 10056222.22 and a median of 12876000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 18.16% in 2025, down 186.88% in 2025.
- Over 3 years, Income from Continuing Operations stood at 8906000.0 in 2024, then tumbled by 69.65% to 15109000.0 in 2025, then retreated by 28.39% to 19398000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 19398000.0, 15109000.0, and 17200000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | -17.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.28 Mn |
| Mar 31, 2026 | -19.40 Mn |
| Dec 31, 2025 | -15.11 Mn |
| Sep 30, 2025 | -17.20 Mn |
| Jun 30, 2025 | -12.90 Mn |
| Mar 31, 2025 | -10.27 Mn |
| Dec 31, 2024 | -8.91 Mn |
| Sep 30, 2024 | -12.88 Mn |
| Jun 30, 2024 | 14.85 Mn |
| Mar 31, 2024 | -8.69 Mn |